I thought this was great news so I wanted to share.
The FDA has approved the use of atezolizumab (Tecentriq) to treat unresectable locally advanced or metastatic triple-negative breast cancer in tumors expressing PD-L1. The immunotherapy had been previously approved for urothelial cancer and non-small cell lung cancer.
Atezolizumab is approved for use with paclitaxel protein-bound.
Roughly 900 patients who hadn’t previously received chemotherapy were randomized to either atezolizumab or placebo infusions. All received paclitaxel protein-bound. Among those with PD-L1-positive tumors, progression-free survival was longer in those receiving atezolizumab (7.4 vs. 4.8 months for placebo).